- Lupin reported a net income of 8.01 billion rupees for the first quarter of 2024, which is a 77% increase year-over-year and higher than the estimated 5.64 billion rupees.
- First-quarter revenue stood at 56 billion rupees, showing a 16% year-over-year increase and surpassing the estimated 52.26 billion rupees.
- North America sales reached 20.4 billion rupees, up 28% year-over-year, exceeding the estimate of 18.14 billion rupees.
- Sales in India amounted to 19.3 billion rupees, an 18% increase year-over-year, above the estimated 17.94 billion rupees.
- EMEA (Europe, Middle East, and Africa) revenue totaled 5.03 billion rupees, marking a 26% increase year-over-year and beating the 4.59 billion rupees estimate.
- Sales of active pharmaceutical ingredients grew by 7.4% year-over-year to 3.62 billion rupees, surpassing the estimate of 3.22 billion rupees.
- Total costs for the quarter were 46.7 billion rupees, rising 9.1% year-over-year.
- Finance costs decreased by 21% year-over-year to 680.1 million rupees, compared to the estimate of 578.6 million rupees.
- Research and Development (R&D) expenses were 3.5 billion rupees, lower than the estimated 4.05 billion rupees.
- Other income surged to 677.8 million rupees from 228 million rupees year-over-year.
- Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 49% year-over-year to 13.1 billion rupees, exceeding the estimated 10.55 billion rupees.
- EBITDA margin improved to 23.7% from 18.5% year-over-year.
- Analyst recommendations include 13 buys, 11 holds, and 12 sells.
A look at Lupin Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Lupin Ltd is positioned with an overall positive outlook for the long term. The company scores moderately across key factors including Value, Dividend, and Growth, indicating a stable foundation. Additionally, Lupin Ltd demonstrates strong Resilience and Momentum, suggesting a favorable market position and potential for sustained growth in the future.
Lupin Limited, known for manufacturing bulk actives and formulations, boasts a diverse portfolio of products including crucial pharmaceuticals such as anti-TB medications, anti-infectives, cardiovascular drugs, and phytomedicines derived from plant sources. With a balanced set of Smart Scores, Lupin Ltd appears well-equipped to navigate market challenges and capitalize on growth opportunities in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
